Literature DB >> 1680401

Successful treatment of tuberculous peritonitis while maintaining patient on CAPD.

D Tan1, P A Fein, A Jorden, M M Avram.   

Abstract

Although conventional wisdom advises removal of the Tenckhoff catheter as part of the therapy for tuberculous peritonitis, there are a few recent reports of cases successfully treated while maintaining the patients on CAPD. We wish to report three cases treated without interrupting CAPD. In two of the patients, cultures were positive for Mycobacterium tuberculosis and in the third case, although the cultures were negative, the patient improved on anti-Tb medications. Smear for AFB was positive in one patient; and two had a positive PPD. All had predominance of lymphocytes and monocytes in effluent. The total WBC count was 160-300 and two patients had fever. All had abdominal pain. One patient was treated with INH and ethambutol; one with INH and rifampin and one (who was suspected of being HIV+) also received pyrazinamide (PZA) until culture was available. Cultures grew in 4-6 weeks. All were started on therapy prior to having the culture results, and all showed clinical improvement within two weeks. One patient had his catheter replaced two months later because of pseudomonas peritonitis, continued on CAPD for an additional five months, then changed to HD because of recurrent bacterial peritonitis. One patient died of complications of diabetic vascular disease three months later with no evidence of peritonitis. One patient has remained on anti-Tb treatment for seven months and is doing well on CAPD.

Entities:  

Mesh:

Year:  1991        PMID: 1680401

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  1 in total

Review 1.  Mycobacterium tuberculous peritonitis in CAPD patients: a report of 11 patients and review of literature.

Authors:  Rapur Ram; Guditi Swarnalatha; Tekin Akpolat; Kalogotla Venkata Dakshinamurty
Journal:  Int Urol Nephrol       Date:  2012-11-10       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.